Institut Pasteur

Robert M Fauve

Luc Montagnier

Jean Igolen

Yvette Henin

Tam Huynh Dinh

Catherine Gouyette

Olivier Schwartz

The glycosylphospholipid nucleoside derivatives of the invention are based on the formula: ##STR1## wherein: R.sub.1 is a nucleoside derivative selected from the group consisting of 3'-azidothymidine (AZT); 2', 3'-dideoxythymidine (ddT); and 2'-deoxy-5-fluorouridine (dFU);

Glycosyl phospholipid derivatives of nucleosides and their use as

The invention relates to a drug active against infections containing in association with a pharmaceutically acceptable carrier, an active principle which is formed of an ose or a polyose product bearing at least one phosphorylated function and at least one diacylated 3-glyceryl-ester function of formula: ##STR1## in which the OCOR and --OCOR' groups, which may be the same or different, are derived from fatty acids.

Phosphorylated 3-glyceryl-esters of glucose

Peptides having immunostimulating properties and pharmaceutical

A suspension of the medicament brought to sufficiently fine particle size to be usable subsequently if necessary in injectable suspensions, is produced in the midst of a liquid in which it is itself insoluble and containing in the dissolved state one or several normally solid non-antigenic organic constituents. The solvent is then removed.

Method of processing an active principle of a hydrophobic medicament and

An immunostimulant from bacterial cells of Salmonella typhimurium or Listeria monocytogenes; it promotes non-specific resistance to pathogens which has no antigenic relationship to the immunostimulant.

Immunostimulant agent from Salmonella typhimurium or Listeria

The immunostimulant agent is extracted from splenic cells of animal origin from Ehrlich ascites cells or from bacteria, such as Bacillus subtilis or Saccharomyces cerevisiae. A suspension of these cells or of these bacteria is formed with a mixture of solvents containing a halogenated hydrocarbon and an alcohol. The insoluble fractions are separated, the liquid fraction evaporated under reduced pressure and at reduced temperature, and the solid residue taken up again in chloroform. The chloroform solution containing the abovementioned immunostimulant agent is recovered by filtration. A suspension in an injectable liquid vehicle of the immunostimulant agent is in the form of particles or micelles whose dimensions are sufficiently small for said suspension to be injectable in man or animal.

Growing community of inventors

Sevres, France

Robert M Fauve